| Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point |
16 |
| On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies |
12 |
| Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond |
11 |
| Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends? |
8 |
| Some statistical considerations in the clinical development of cancer immunotherapies |
8 |
| Propensity-score-based priors for Bayesian augmented control design |
7 |
| Effect of heteroscedasticity between treatment groups on mixed-effects models for repeated measures |
6 |
| Propensity score matched augmented controls in randomized clinical trials: A case study |
6 |
| Better decision making in drug development through adoption of formal prior elicitation |
5 |
| BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes |
5 |
| Bayesian detection of potential risk using inference on blinded safety data |
5 |
| A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint |
5 |
| Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate |
5 |
| Covariate adjustment and estimation of mean response in randomised trials |
5 |
| Approaches to sample size calculation for clinical trials in rare diseases |
4 |
| Blinded continuous monitoring in clinical trials with recurrent event endpoints |
4 |
| Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects |
4 |
| How to use prior knowledge and still give new data a chance? |
4 |
| On weighted composite scores for early Alzheimer's trials |
4 |
| Estimating the variance for heterogeneity in arm-based network meta-analysis |
3 |
| Understanding the influence of individual variables contributing to multivariate outliers in assessments of data quality |
3 |
| Missing data handling in non-inferiority and equivalence trials: A systematic review |
3 |
| Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations |
3 |
| Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects |
3 |
| A flexible parametric survival model for fitting time to event data in clinical trials |
3 |
| Equilibrium, affinity, dissociation constants, IC5O: Facts and fantasies |
2 |
| Points to consider for analyzing efficacy outcomes in long-term extension clinical trials |
2 |
| Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination |
2 |
| Effect of a statistical outlier in potency bioassays |
2 |
| Design considerations in clinical trials with cure rate survival data: A case study in oncology |
2 |
| Tests for noninferiority trials with binomial endpoints: A guide to modern and quasi-exact methods for biomedical researchers |
2 |
| Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis |
2 |
| Reference-based sensitivity analysis for time-to-event data |
2 |
| Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment |
2 |
| How can we make better graphs? An initiative to increase the graphical expertise and productivity of quantitative scientists |
2 |
| Optimal planning of phase II/III programs for clinical trials with multiple endpoints |
2 |
| Sample size allocation in multiregional equivalence studies |
2 |
| A proposal for a new PhD level curriculum on quantitative methods for drug development |
2 |
| Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development |
2 |
| Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis |
2 |
| Estimation of discrete survival function for error-prone diagnostic tests |
1 |
| The plan of enrichment designs for dealing with high placebo response |
1 |
| A simple, doubly robust, efficient estimator for survival functions using pseudo observations |
1 |
| Antibiotics to outpatients in NorwayAssessing effect of latitude and municipality population size using quantile regression in a cross-sectional study |
1 |
| A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes |
1 |
| Phase 3 adaptive trial design options in treatment of complicated urinary tract infection |
1 |
| A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area |
1 |
| A practical guide to pre-trial simulations for Bayesian adaptive trials using SAS and BUGS |
1 |
| Bayesian joint modelling of benefit and risk in drug development |
1 |
| An evaluation of the trimmed mean approach in clinical trials with dropout |
1 |
